12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Sanofi sales and marketing update

Sanofi's Genzyme Corp. unit said it began shipping Fabry's disease therapy Fabrazyme agalsidase beta manufactured at its newly approved Framingham, Mass., facility. The company said U.S. patients will able...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >